Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its competitors? We will compare Arcturus Therapeutics to similar companies based on the strength of its earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and valuation.
Institutional & Insider Ownership
94.5% of Arcturus Therapeutics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 17.8% of Arcturus Therapeutics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Volatility and Risk
Arcturus Therapeutics has a beta of 2.62, indicating that its stock price is 162% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics’ competitors have a beta of 1.15, indicating that their average stock price is 15% more volatile than the S&P 500.
Profitability
This table compares Arcturus Therapeutics and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Arcturus Therapeutics | -285.92% | -45.35% | -35.33% |
| Arcturus Therapeutics Competitors | -12,357.18% | -197.96% | -30.56% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Arcturus Therapeutics and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Arcturus Therapeutics | 1 | 1 | 6 | 2 | 2.90 |
| Arcturus Therapeutics Competitors | 9834 | 15121 | 45433 | 1587 | 2.54 |
Arcturus Therapeutics currently has a consensus price target of $22.29, suggesting a potential upside of 115.32%. As a group, “Biotechnology” companies have a potential upside of 102.61%. Given Arcturus Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Arcturus Therapeutics is more favorable than its competitors.
Earnings and Valuation
This table compares Arcturus Therapeutics and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Arcturus Therapeutics | $82.03 million | -$65.78 million | -3.36 |
| Arcturus Therapeutics Competitors | $716.53 million | $12.10 million | -15.00 |
Arcturus Therapeutics’ competitors have higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Summary
Arcturus Therapeutics beats its competitors on 9 of the 13 factors compared.
Arcturus Therapeutics Company Profile
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Receive News & Ratings for Arcturus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcturus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
